Antireflux Surgery Preserves Lung Function in Patients With Gastroesophageal Reflux Disease and End-stage Lung Disease Before and After Lung Transplantation

Hoppo, Toshitaka; Jarido, Veronica; Pennathur, Arjun; Morrell, Matthew R.; Crespo, Maria; Shigemura, Norihisa; Bermúdez, C.; Hunter, John G.; Toyoda, Yoshiya; Pilewski, Joseph M.; Luketich, James D.; Jobe, Blair A.

doi:10.1001/archsurg.2011.216

Cited by 135 publications

(74 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Hoppo et al evaluated 19 patients with GERD and ESLD before lung transplant and found that 1 year after LARS the FEV 1 improved in 85% of them and that episodes of pneumonia and acute rejection stabilized. 21 Longer survival in patients with IPF taking PPI or after Nissen fundoplication was also documented by Lee et al 22 To further clarify the effect of reflux control in patients with GERD and IPF, the National Institutes of Health is sponsoring a phase II multicenter study of laparoscopic fundoplication for the treatment of GERD in IPF patients (University of California San Francisco; University of Washington, Seattle; University of Michigan; University of Wisconsin, Madison; and University of Chicago). This study aims to determine if by blocking reflux the natural history of the disease can be changed, and specifically, it aims to determine the impact of LARS on the decline of forced vital capacity (FVC) to determine the safety of LARS in patients with IPF.…”

Section: Evidence That Antireflux Surgery In Patients With Ipf Can Blmentioning

confidence: 80%

The Intersection of GERD, Aspiration, and Lung Transplantation

Patti

Vela

Odell

et al. 2016

Journal of Laparoendoscopic & Advanced Surgical Techniques

View full text Add to dashboard Cite

Lung transplantation is a radical but life-saving treatment option for patients with end-stage lung diseases, such as idiopathic pulmonary fibrosis (IPF) and scleroderma. In light of the proposed association and controversy linking gastroesophageal reflux disease (GERD) to IPF and lung transplant outcome, the American Gastroenterological Association convened during the DDW in Washington in May 2015 a multidisciplinary group of experts in the field of GERD and lung transplantation to make considerations about the care of these patients based on available data and subsequent expert panel discussion at this symposium. The following topics were discussed: (1) pathophysiology of GERD-induced pulmonary symptoms, (2) GERD evaluation before and after lung transplantation, (3) outcome of lung transplantation for IPF and scleroderma, and (4) role of laparoscopic fundoplication before or after lung transplantation.

show abstract

Section: Evidence That Antireflux Surgery In Patients With Ipf Can Blmentioning

confidence: 80%

The Intersection of GERD, Aspiration, and Lung Transplantation

Patti

Vela

Odell

et al. 2016

Journal of Laparoendoscopic & Advanced Surgical Techniques

View full text Add to dashboard Cite

show abstract

“…Nissen fundoplication and Toupet fundoplication) can be performed safely on lung transplant candidates with advanced lung disease or lung transplant recipients with documented abnormal GOR [123,124,[127][128][129][132][133][134][135][136][137][138], thereby preventing reflux, aspiration of gastric secretions and related sequelae.…”

Section: Remarksmentioning

confidence: 99%

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

et al. 2014

View full text Add to dashboard Cite

Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is associated with poor survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society convened a committee of international experts to describe and/or provide recommendations for 1) the definition of BOS, 2) the risk factors for developing BOS, 3) the diagnosis of BOS, and 4) the management and prevention of BOS.A pragmatic evidence synthesis was performed to identify all unique citations related to BOS published from 1980 through to March, 2013. The expert committee discussed the available research evidence upon which the updated definition of BOS, identified risk factors and recommendations are based. The committee followed the GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach to develop specific clinical recommendations.The term BOS should be used to describe a delayed allograft dysfunction with persistent decline in forced expiratory volume in 1 s that is not caused by other known and potentially reversible causes of posttransplant loss of lung function. The committee formulated specific recommendations about the use of systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and about re-transplantation in patients with suspected and confirmed BOS.The diagnosis of BOS requires the careful exclusion of other post-transplant complications that can cause delayed lung allograft dysfunction, and several risk factors have been identified that have a significant association with the onset of BOS. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Adequately designed and executed randomised controlled trials that properly measure and report all patient-important outcomes are needed to identify optimal therapies for established BOS and effective strategies for its prevention. Executive summaryMany lung transplant recipients develop delayed allograft dysfunction that has been traditionally referred to as bronchiolitis obliterans syndrome (BOS), which is thought to be caused by inflammation, destruction and fibrosis of small airways in the lung allograft that leads to obliterative bronchiolitis (OB). Because a definitive diagnosis of OB is difficult to make without a surgical lung biopsy, a decrease in the forced expiratory volume in 1 s (FEV1) has been used as a surrogate marker to identify patients who develop a syndrome of significant and persistent loss of lung allograft function with onset three or more months following transplantation. However, it is now recognised that numerous factors apart from OB can lead to a delayed onset, significant decline in lung function, and these causes of delayed onset graft dysfunction must be carefully excluded when a diagnosis of BOS is made. In general, BOS responds poorly to therapeutic interventions but may stabilise, and some patients may have a significant improvement in FEV1 with certain ther...

show abstract

“…Patients with ESLD, in particular, the IPF population, are known to have elevated rates of GERD [2,4,10,11,16,[26][27][28]. These rates will continue to increase after lung transplantation [15,17,18,20,21,[29][30][31].…”

Section: Discussionmentioning

confidence: 99%

721 Pepsin Concentrations Are Elevated in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis after Lung Transplantation

Davis

Flint

Pelletiere

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Background-Aspiration of gastroesophageal refluxate has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the progression of bronchiolitis obliterans syndrome after lung transplantation. The goals of the present study were to identify lung transplant patients at the greatest risk of aspiration and to investigate the causative factors. Materials and methods-FromSeptember 2009 to November 2011, 252 bronchoalveolar lavage fluid (BALF) samples were collected from 100 lung transplant patients. The BALF pepsin concentrations and the results of transbronchial biopsy, esophageal function testing, barium swallow, and gastric emptying scan were compared among those with the most common end-stage lung diseases requiring lung transplantation: IPF, chronic obstructive pulmonary disease, cystic fibrosis, and α 1 -antitrypsin deficiency.Results-Patients with IPF had higher BALF pepsin concentrations and a greater frequency of acute rejection than those with α 1 -antitrypsin deficiency, cystic fibrosis, or chronic obstructive pulmonary disease (P = 0.037). Moreover, the BALF pepsin concentrations correlated negatively with a lower esophageal sphincter pressure and distal esophageal amplitude; negatively with distal esophageal amplitude and positively with total esophageal acid time, longest reflux episode, and DeMeester score in those with chronic obstructive pulmonary disease; and negatively with the upright acid clearance time in those with IPF. Conclusions-Our

show abstract

Antireflux Surgery Preserves Lung Function in Patients With Gastroesophageal Reflux Disease and End-stage Lung Disease Before and After Lung Transplantation

Cited by 135 publications

References 29 publications

The Intersection of GERD, Aspiration, and Lung Transplantation

The Intersection of GERD, Aspiration, and Lung Transplantation

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

721 Pepsin Concentrations Are Elevated in the Bronchoalveolar Lavage Fluid of Patients with Idiopathic Pulmonary Fibrosis after Lung Transplantation

Contact Info

Product

Resources

About